Inclusion Criteria:
- Eligible for treatment with cilta-cel per United States Prescribing Information (USPI)
- Has serious or life-threatening multiple myeloma per USPI, and where re-apheresis,
re-manufacturing, or other anti-myeloma directed therapy is not considered feasible or
adequate per treating physician discretion
- Favorable participant benefit/risk assessment determined by Janssen medical review
- Treating physician confirms the favorable risk benefit profile, and that proceeding
with this treatment is in the best interest of the participant
- Able to provide informed consent indicating they understand the purpose of this
expanded access program (EAP)
- A woman of childbearing potential must have a negative highly sensitive serum
(beta-human chorionic gonadotropin [beta-hCG]) pregnancy test during screening and
prior to the first dose of cyclophosphamide and fludarabine